The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study için istatistikler
Toplam ziyaret
| views | |
|---|---|
| The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study | 1 |
Aylık toplam ziyaret
| views | |
|---|---|
| Aralık 2025 | 0 |
| Ocak 2026 | 0 |
| Şubat 2026 | 0 |
| Mart 2026 | 0 |
| Nisan 2026 | 0 |
| Mayıs 2026 | 0 |
| Haziran 2026 | 0 |
